Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $57.3 million.

  • Harmony Biosciences Holdings' Accumulated Expenses rose 303.00% to $57.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.3 million, marking a year-over-year increase of 303.00%. This contributed to the annual value of $51.7 million for FY2024, which is 47.99% down from last year.
  • Harmony Biosciences Holdings' Accumulated Expenses amounted to $57.3 million in Q3 2025, which was up 60.20% from $35.8 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Accumulated Expenses ranged from a high of $99.5 million in Q4 2023 and a low of $7.3 million during Q1 2024.
  • In the last 3 years, Harmony Biosciences Holdings' Accumulated Expenses had a median value of $51.7 million in 2024 and averaged $45.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 87.12% in 2024, then skyrocketed by 303.95% in 2025.
  • Harmony Biosciences Holdings' Accumulated Expenses (Quarterly) stood at $40.2 million in 2021, then slumped by 36.97% to $25.4 million in 2022, then soared by 292.22% to $99.5 million in 2023, then crashed by 47.99% to $51.7 million in 2024, then skyrocketed by 303.00% to $57.3 million in 2025.
  • Its last three reported values are $57.3 million in Q3 2025, $35.8 million for Q2 2025, and $29.6 million during Q1 2025.